MX2017000222A - Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. - Google Patents
Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.Info
- Publication number
- MX2017000222A MX2017000222A MX2017000222A MX2017000222A MX2017000222A MX 2017000222 A MX2017000222 A MX 2017000222A MX 2017000222 A MX2017000222 A MX 2017000222A MX 2017000222 A MX2017000222 A MX 2017000222A MX 2017000222 A MX2017000222 A MX 2017000222A
- Authority
- MX
- Mexico
- Prior art keywords
- preventing
- promoting
- treating
- compositions
- diabetes
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001737 promoting effect Effects 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 230000004584 weight gain Effects 0.000 title abstract 2
- 235000019786 weight gain Nutrition 0.000 title abstract 2
- 230000004580 weight loss Effects 0.000 title abstract 2
- MZOPWQKISXCCTP-UHFFFAOYSA-N Malonoben Chemical compound CC(C)(C)C1=CC(C=C(C#N)C#N)=CC(C(C)(C)C)=C1O MZOPWQKISXCCTP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Se divulgan cepas equipos que incluyen un desacoplador químico, tal como tirfostina 9 o su precursor o sal, y composiciones que incluyen un desacoplador químico, tal como tirfostina 9 en combinación con uno o más agentes terapéuticos, por ejemplo, L-carnitina, que son útiles, por ejemplo, en el tratamiento de la obesidad, la prevención del aumento de peso, la promoción de la pérdida de peso/adelgazamiento, y/o el tratamiento o la prevención del desarrollo de diabetes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020797P | 2014-07-03 | 2014-07-03 | |
| US201562127111P | 2015-03-02 | 2015-03-02 | |
| PCT/US2015/039075 WO2016004363A2 (en) | 2014-07-03 | 2015-07-02 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017000222A true MX2017000222A (es) | 2017-12-07 |
Family
ID=55016229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000222A MX2017000222A (es) | 2014-07-03 | 2015-07-02 | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. |
| MX2021015661A MX2021015661A (es) | 2014-07-03 | 2017-01-04 | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015661A MX2021015661A (es) | 2014-07-03 | 2017-01-04 | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10849872B2 (es) |
| EP (1) | EP3164125B8 (es) |
| JP (2) | JP6887252B2 (es) |
| CN (2) | CN106604725B (es) |
| AU (2) | AU2015283905B2 (es) |
| BR (1) | BR112016030983A8 (es) |
| CA (1) | CA2954004C (es) |
| CO (1) | CO2017001025A2 (es) |
| DK (1) | DK3164125T3 (es) |
| ES (1) | ES2965033T3 (es) |
| FI (1) | FI3164125T3 (es) |
| HR (1) | HRP20231572T1 (es) |
| HU (1) | HUE064714T2 (es) |
| MX (2) | MX2017000222A (es) |
| PE (1) | PE20170470A1 (es) |
| PT (1) | PT3164125T (es) |
| RU (1) | RU2745440C2 (es) |
| WO (1) | WO2016004363A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| EP3554285A4 (en) | 2016-11-29 | 2021-01-20 | University of Iowa Research Foundation | USE OF NAD PRECURSORS TO IMPROVE MATERNAL HEALTH AND / OR DESCENDANT HEALTH |
| UA124026C2 (uk) | 2017-01-06 | 2021-07-07 | Рівус Фармасьютікалс, Інк. | Фенільні похідні |
| CN107212225A (zh) * | 2017-06-02 | 2017-09-29 | 陈玉霞 | 一种用于瘦身的玫瑰茄固体饮料及其制备方法 |
| US10226442B2 (en) * | 2017-07-10 | 2019-03-12 | Syneurx International (Taiwan) Corp. | Lithium salts of N-substituted glycine compounds and uses thereof |
| WO2019083297A1 (ko) * | 2017-10-26 | 2019-05-02 | 주식회사 네비팜 | 간질환 예방 또는 치료용 의약 조성물 |
| CN108272903A (zh) * | 2018-03-15 | 2018-07-13 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种减肥配方及其应用方法 |
| AU2019239797B2 (en) * | 2018-03-20 | 2024-04-04 | Exerkine Corporation | Weight management composition |
| TWI710766B (zh) * | 2018-08-13 | 2020-11-21 | 國立臺灣大學 | 使用口服肉鹼耐量試驗以測定一個體內氧化三甲胺產能之檢測方法 |
| CR20240141A (es) * | 2021-08-25 | 2024-05-28 | Garcia Sada Fernando | Composiciones y métodos para prevenir o reducir el riesgo del síndrome metabólico |
| CN118542463A (zh) * | 2024-07-25 | 2024-08-27 | 浙江衡美健康科技股份有限公司 | 快速减重的高脂肪组合物、制备方法及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3810994A (en) * | 1972-06-01 | 1974-05-14 | Ethyl Corp | Method and composition for treating obesity |
| IT1156852B (it) | 1978-07-10 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Procedimento industriale per la preparazione del d'canforato della l carnitinammide e del d canforato della d carnitinammide e sue applicazioni |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| DE3463261D1 (en) | 1983-12-28 | 1987-05-27 | Sigma Tau Ind Farmaceuti | Salts of l-carnitine and alkanoyl l-carnitines and process for preparing same |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| AU632992B2 (en) | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| IT1256705B (it) | 1992-12-21 | 1995-12-12 | Sigma Tau Ind Farmaceuti | Procedimento per la preparazione di l-(-)-carnitina a partire da un prodotto di scarto avente opposta configurazione. |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| ES2322328T3 (es) | 1999-09-03 | 2009-06-19 | Sigma-Tau Healthscience S.P.A. | L-carnitina ultrafina, procedimientos de preparacion, composiciones que la contienen y procedimiento de uso de la misma. |
| DE10055940A1 (de) | 2000-11-10 | 2002-05-29 | Bayer Ag | Neue Indanylidenverbindungen |
| WO2004041256A2 (en) | 2002-11-08 | 2004-05-21 | Novo Nordisk A/S | Safe chemical uncouplers for the treatment of obesity |
| BRPI0508936A (pt) * | 2004-03-17 | 2007-09-25 | Nestec Sa | composições e métodos para redução ou prevenção de obesidade |
| EP1774028A4 (en) | 2004-07-07 | 2008-05-07 | Dana Farber Cancer Inst Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OBESITY |
| RU2342115C2 (ru) | 2006-12-28 | 2008-12-27 | Федеральное государственное учреждение "Томский научно-исследовательский институт курортологии и физиотерапии Федерального агентства по здравоохранению и социальному развитию" (ФГУ "ТНИИКиФ Росздрава) | Способ комплексного лечения детей с ожирением |
| WO2010022236A2 (en) * | 2008-08-20 | 2010-02-25 | The University Of Medicine And Dentistry Of New Jersey | Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor |
-
2015
- 2015-07-02 PT PT158155853T patent/PT3164125T/pt unknown
- 2015-07-02 RU RU2017103450A patent/RU2745440C2/ru active
- 2015-07-02 AU AU2015283905A patent/AU2015283905B2/en active Active
- 2015-07-02 US US14/790,824 patent/US10849872B2/en active Active
- 2015-07-02 PE PE2017000004A patent/PE20170470A1/es unknown
- 2015-07-02 BR BR112016030983A patent/BR112016030983A8/pt not_active Application Discontinuation
- 2015-07-02 EP EP15815585.3A patent/EP3164125B8/en active Active
- 2015-07-02 DK DK15815585.3T patent/DK3164125T3/da active
- 2015-07-02 ES ES15815585T patent/ES2965033T3/es active Active
- 2015-07-02 FI FIEP15815585.3T patent/FI3164125T3/fi active
- 2015-07-02 CA CA2954004A patent/CA2954004C/en active Active
- 2015-07-02 CN CN201580047257.5A patent/CN106604725B/zh active Active
- 2015-07-02 JP JP2016576053A patent/JP6887252B2/ja active Active
- 2015-07-02 MX MX2017000222A patent/MX2017000222A/es unknown
- 2015-07-02 HU HUE15815585A patent/HUE064714T2/hu unknown
- 2015-07-02 CN CN202110646408.6A patent/CN113387836A/zh active Pending
- 2015-07-02 WO PCT/US2015/039075 patent/WO2016004363A2/en active Application Filing
- 2015-07-02 HR HRP20231572TT patent/HRP20231572T1/hr unknown
-
2017
- 2017-01-04 MX MX2021015661A patent/MX2021015661A/es unknown
- 2017-02-03 CO CONC2017/0001025A patent/CO2017001025A2/es unknown
-
2020
- 2020-04-09 JP JP2020070284A patent/JP7171644B2/ja active Active
- 2020-11-30 US US17/106,908 patent/US20210186918A1/en not_active Abandoned
-
2021
- 2021-01-20 AU AU2021200355A patent/AU2021200355B2/en active Active
-
2023
- 2023-10-23 US US18/382,997 patent/US20240066001A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015661A (es) | Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes. | |
| PH12017502107A1 (en) | Triazole agonists of the apj receptor | |
| EA201591743A1 (ru) | СТИМУЛЯТОРЫ sGC | |
| MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
| MX2018015657A (es) | Compuestos heterociclico como antibacterianos. | |
| MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
| NZ710444A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| NZ720769A (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| MX2021008318A (es) | Nuevos polipeptidos de union especifica y usos de los mismos. | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| SG11201705450SA (en) | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases | |
| MX2019012285A (es) | Metodos de tratamiento de encefalopatias del desarrollo. | |
| MX2017005249A (es) | Compuestos para usarse en el tratamiento antihelmintico. | |
| BR112017022022A8 (pt) | Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas) | |
| MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
| EA033460B1 (ru) | Замещенные [1,2,4]триазольные соединения в качестве фунгицидов | |
| MX2017001047A (es) | Compuestos para usar en el tratamiento antihelmintico. | |
| MX2017004819A (es) | Metodos de tratamiento de transtornos urológicos usando sarm. | |
| UA117524C2 (uk) | Стимулятори рослин, їх застосування та спосіб стимуляції рослин | |
| EA201790902A1 (ru) | Способ получения комплекса железа(iii) с n-ацетиласпартилированным казеином и его применение в фармацевтических композициях | |
| MA40388A (fr) | Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète | |
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs | |
| MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci |